Replimune Group (REPL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Jul, 2026Executive summary
The 2026 Annual Meeting will be held virtually on September 15, 2026, with all stockholders of record as of July 21, 2026, eligible to participate and vote online.
Proxy materials, including the proxy statement and annual report, are available electronically, with voting accessible via internet, phone, or mail.
The Board recommends voting in favor of all three proposals: auditor ratification, executive compensation approval, and an amendment to increase authorized shares.
Voting matters and shareholder proposals
Proposal 1: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending March 31, 2027.
Proposal 2: Non-binding advisory approval of named executive officer compensation for fiscal year ended March 31, 2026.
Proposal 3: Amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
Board unanimously recommends voting “FOR” all proposals.
Stockholders may submit proposals or director nominations for the 2027 meeting by following bylaw procedures.
Board of directors and corporate governance
Board consists of ten members, divided into three staggered classes; two Class II vacancies will be created after the meeting as Mr. Pucci and Ms. Peeples-Dyer are not standing for reelection.
Majority of directors are independent per Nasdaq and SEC standards; all committee members are independent.
Board leadership includes an Executive Chairman, CEO, and Lead Independent Director.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Research & Development.
Board and committees met regularly, with all directors attending at least 75% of meetings.
Latest events from Replimune Group
- Directors were elected, key proposals passed except the incentive plan amendment.REPL
AGM 20259 Jul 2026 - RP1 plus nivolumab achieved a 33.6% ORR and durable responses in anti-PD1 failed melanoma.REPL
Study Result9 Jul 2026 - RP1 shows 34% response in anti-PD-1 failed melanoma, with global launch and expansion planned.REPL
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical results.REPL
Q4 202629 Jun 2026 - Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress.REPL
Leerink Global Healthcare Conference 20269 Mar 2026 - Net loss rose to $70.9M, FDA review of RP1 advances, and cash runway extends into Q1 2027.REPL
Q3 20263 Feb 2026 - RP1 and RP2 show strong efficacy in tough cancers, with regulatory and commercial progress ongoing.REPL
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Oncolytic immunotherapy nears launch with strong efficacy and broad pipeline expansion.REPL
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Up to $250M in securities, including $100M ATM, to fund late-stage cancer immunotherapy pipeline.REPL
Registration Filing16 Dec 2025